Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.23.5 (
cathepsin D
)
4,130
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The cleavage of the amyloid precursor protein (APP) into amyloidogenic components (Abeta) is a central event in the pathogenesis of Alzheimer's disease (AD).
FE65
is a protein that is involved in APP metabolism and may facilitate the production of Abeta. Recently, an intronic polymorphism of the gene encoding
FE65
(
FE65
) was associated with altered risk for the development of sporadic AD. In our sample of 102 AD patients and 351 non-demented controls we did not replicate the association between
FE65
and AD. Moreover, we observed no risk-modifying interaction and no linkage disequilibrium between
FE65
and the gene encoding the acid protease
cathepsin D
(
catD
), which - like
FE65
- is involved in APP metabolism and is also located on chromosome 11p15. We conclude that, whereas
FE65
is implicated in AD pathology, the gene encoding
FE65
does not appear to confer a substantial risk for AD.
...
PMID:No association between an intronic biallelic polymorphism of the FE65 gene and Alzheimer's disease. 1102 29